Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2012
09/06/2012US20120225867 Androgen receptor modulating compounds
09/06/2012US20120225866 Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation
09/06/2012US20120225865 Arylcyclohexylethers of dihydrotetraazabenzoazulenes
09/06/2012US20120225864 Methods and Compositions for Modulating Tau Levels
09/06/2012US20120225863 Heterocyclic compounds for the inhibition of pask
09/06/2012US20120225862 Heteroaryl benzamides, compositions and methods of use
09/06/2012US20120225861 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling
09/06/2012US20120225860 Method for administration of a gamma secretase inhibitor
09/06/2012US20120225859 Pyrimidine derivatives used as pi-3 kinase inhibitors
09/06/2012US20120225858 1,4 thiazepines/sulfones as bace1 and/or bace2 inhibitors
09/06/2012US20120225857 Mst1 kinase inhibitors and methods of their use
09/06/2012US20120225856 Fused ring azadecalin glucocorticoid receptor modulators
09/06/2012US20120225855 Triazolopyridine jak inhibitor compounds and methods
09/06/2012US20120225854 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes
09/06/2012US20120225853 Hormone replacement therapy and depression
09/06/2012US20120225852 Use of steroid compounds
09/06/2012US20120225851 Compositions and methods useful for treating diseases
09/06/2012US20120225850 Steroidal antitubercular compounds
09/06/2012US20120225849 2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition
09/06/2012US20120225848 Antagonists of GABA-B Receptors to Enhance Neuronal Function, Learning and Memory
09/06/2012US20120225847 Squaric acid derivatives as inhibitors of the nicotinamide
09/06/2012US20120225846 Heterocyclic compounds for the inhibition of pask
09/06/2012US20120225845 Compounds for diseases and disorders
09/06/2012US20120225844 Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors
09/06/2012US20120225843 Use of Sulfated Glycosaminoglycans for Establishing Effective Labor in Women
09/06/2012US20120225842 Hyaluronic acid compositions for dermatological use
09/06/2012US20120225841 Methods of Making and Using a Ruminant Gas Reduction Composition
09/06/2012US20120225840 Hydroxytyrosol combinations for enhancing mitochondrial function and energy production
09/06/2012US20120225839 Phosphoramidate Derivatives of Nucleosides
09/06/2012US20120225838 Anti-tumor effect potentiator
09/06/2012US20120225837 Medicinal agent for disease associated with epstein-barr virus, and method for screening of the medicinal agent
09/06/2012US20120225836 Compositions comprising decitabine and tetrahydrouridine and uses thereof
09/06/2012US20120225835 Antibiotic formulations, unit doses, kits, and methods
09/06/2012US20120225834 Ocular iontophoresis of charged micelles containing bioactive agents
09/06/2012US20120225833 Composition for treating mental health disorders
09/06/2012US20120225832 Amphiphilic Compositions and Methods for Preparing and Using Same
09/06/2012US20120225827 Silicone-based ophthalmic formulations
09/06/2012US20120225826 Transporters Comprising Spaced Arginine Moieties
09/06/2012US20120225812 Substituted fused pyrimidine compounds, its preparation and uses thereof
09/06/2012US20120225776 Crystalline Modification of Fipronil
09/06/2012US20120225402 Novel dental appliances and methods for their fabrication
09/06/2012US20120225144 Herbal Supplement Prepared From Geranium
09/06/2012US20120225142 Herbal Supplement Prepared From Pelargonium Citronellum
09/06/2012US20120225136 Inhibition of tumour cell migration
09/06/2012US20120225132 Methods for Increasing the Kinetic Activity of Alcohol, Water and Other Liquids, so as to Render the Liquids More Capable of Enhancing the Alternative Cellular Energy Pathway in the Prevention and Therapy of Diseases
09/06/2012US20120225129 Conjugates, particles, compositions, and related methods
09/06/2012US20120225128 Method for carrying therapeutic substances into cells
09/06/2012US20120225124 Stable laquinimod preparations
09/06/2012US20120225123 Use of Synergistic Combinations of an Avermectin and an Antineoplastic Compounds for the Treatment of Hematological Malignancies
09/06/2012US20120225122 Abuse-Resistant Formulations
09/06/2012US20120225121 Bioequivalent formulation of efavirenz
09/06/2012US20120225120 Stable pharmaceutical composition and methods of using same
09/06/2012US20120225119 Therapeutic combination for painful medical conditions
09/06/2012US20120225118 Compositions for delivery of insoluble agents
09/06/2012US20120225117 Process for production of w/o/w emulsion, process for production of liposome employing the process, and porous membrane for use in the processes
09/06/2012US20120225115 Methods and Compositions for Improved Deliver, Expression or Activity of RNA Interference Agents
09/06/2012US20120225114 Modifying Macrophage Phenotype for Treatment of Disease
09/06/2012US20120225113 Method for treating tuberculosis
09/06/2012US20120225112 Method and Apparatus for Alcohol Administration
09/06/2012US20120225108 Products for improving wound healing
09/06/2012US20120225105 Sugar-based dispersion
09/06/2012US20120225103 Transdermal Therapeutic System Containing a Pramipexol Active Agent
09/06/2012US20120225102 Perfluorocarbon gel formulations
09/06/2012US20120225101 Multifunctional in situ polymerized network via thiol-ene and thiol-maleimide chemistry
09/06/2012US20120225100 Articlea and processes for Making a Porous Disintegratable Solid Substrate for Personal Health Care Applications
09/06/2012US20120225098 Biofilm inhibiting composition
09/06/2012US20120225097 Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
09/06/2012US20120225093 Abrogating HIV-1 Infection via Drug-Induced Reactivation of Apoptosis
09/06/2012US20120225088 Compositions and methods for treating cancer and other diseases
09/06/2012US20120225078 Immune system modulating composition
09/06/2012US20120225076 Fra-1 target genes as drug targets for treating cancer
09/06/2012US20120225062 Novel kinase inhibitors
09/06/2012US20120225061 Tetrasubstituted cyclohexyl compounds as kinase inhibitors
09/06/2012US20120225059 Novel Agents and Uses Thereof
09/06/2012US20120225057 Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
09/06/2012US20120225053 Compositions and methods for the prevention and treatment of conditions associated with inflamation
09/06/2012US20120225052 Composition and method for treating tissue defects
09/06/2012US20120225049 Fast acting snare-cleaving enzymes
09/06/2012US20120225034 Agents useful in treating facioscapulohumeral muscular dystrophy
09/06/2012US20120225033 Biodegradable Drug Delivery Composition
09/06/2012US20120225031 Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
09/06/2012US20120225030 Uses of mammalian cytokine; related reagents
09/06/2012US20120225027 Toxicity enhancing compounds and methods
09/06/2012US20120225017 Mixed micelles
09/06/2012US20120225014 Antibodies to cd40
09/06/2012US20120225012 Composition for hard tissue repair
09/06/2012DE112010003084T5 Fulvestrant in einer Dosierung von 500 mg zur Behandlung von fortgeschrittenem Brustkrebs Fulvestrant at a dosage of 500 mg for the treatment of advanced breast cancer
09/06/2012DE102011012712A1 Verwendung von Aldosteron-Rezeptor-Antagonisten zur Behandlung von weiblicher sexueller Dysfunktion Use of aldosterone receptor antagonists for the treatment of female sexual dysfunction
09/06/2012DE102011004899A1 New 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl-deriva tives are progesterone receptor antagonists useful to treat and prevent e.g. uterine fibroids, endometriosis, heavy menstrual bleeding and meningioma
09/05/2012EP2495569A1 Method for determination of sensitivity to anti-cancer agent
09/05/2012EP2495568A1 Method for determining sensitivity to an anticancer agent
09/05/2012EP2495561A1 Anticancer agent sensitivity-determining marker
09/05/2012EP2495327A2 Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
09/05/2012EP2495324A2 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
09/05/2012EP2495323A1 Modified double-stranded polynucleotide
09/05/2012EP2495248A1 Bridged artificial nucleoside and nucleotide
09/05/2012EP2495245A2 Gram-positive carbapenem antibacterials and processes for their preparation
09/05/2012EP2495244A1 Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors
09/05/2012EP2495243A1 Novel 5-fluorouracil derivative
09/05/2012EP2495242A2 Novel vascular leak inhibitor
1 ... 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 ... 7860